Cargando…
Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report
INTRODUCTION: There is little evidence regarding the treatment of stage IVB endometrial cancer. Therefore, chemotherapy is more likely to be chosen as the initial and first-line treatment. Pembrolizumab is a new treatment choice for unresectable endometrial cancer after first-line chemotherapy failu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118171/ https://www.ncbi.nlm.nih.gov/pubmed/35658296 http://dx.doi.org/10.1016/j.ijscr.2022.107125 |
_version_ | 1784710456926011392 |
---|---|
author | Taguchi, Tomomi Ito, Kimihiko Yamashita, Michiko Egawa-Takata, Tomomi |
author_facet | Taguchi, Tomomi Ito, Kimihiko Yamashita, Michiko Egawa-Takata, Tomomi |
author_sort | Taguchi, Tomomi |
collection | PubMed |
description | INTRODUCTION: There is little evidence regarding the treatment of stage IVB endometrial cancer. Therefore, chemotherapy is more likely to be chosen as the initial and first-line treatment. Pembrolizumab is a new treatment choice for unresectable endometrial cancer after first-line chemotherapy failure. PRESENTATION OF CASE: Herein, we report the case of a 56-year-old patient diagnosed with stage IVB endometrial cancer. After eight cycles of first-line chemotherapy, computed tomography (CT) revealed relapse with re-enlargement of the para-aortic lymph nodes. Since the primary tumour had high microsatellite instability, we switched to pembrolizumab treatment. Pembrolizumab was effective but could not be continued due to adverse events after 10 cycles. Positron emission tomography-CT revealed active cancer in the uterus and para-aortic lymph nodes. DISCUSSION: Since pembrolizumab treatment had to be discontinued, we performed salvage surgery, which achieved complete tumour removal, and the patient has had no evidence of disease for 16 months. CONCLUSION: This is the first case of complete surgical resection after administering pembrolizumab as a second-line treatment for advanced endometrial cancer. |
format | Online Article Text |
id | pubmed-9118171 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-91181712022-05-20 Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report Taguchi, Tomomi Ito, Kimihiko Yamashita, Michiko Egawa-Takata, Tomomi Int J Surg Case Rep Case Report INTRODUCTION: There is little evidence regarding the treatment of stage IVB endometrial cancer. Therefore, chemotherapy is more likely to be chosen as the initial and first-line treatment. Pembrolizumab is a new treatment choice for unresectable endometrial cancer after first-line chemotherapy failure. PRESENTATION OF CASE: Herein, we report the case of a 56-year-old patient diagnosed with stage IVB endometrial cancer. After eight cycles of first-line chemotherapy, computed tomography (CT) revealed relapse with re-enlargement of the para-aortic lymph nodes. Since the primary tumour had high microsatellite instability, we switched to pembrolizumab treatment. Pembrolizumab was effective but could not be continued due to adverse events after 10 cycles. Positron emission tomography-CT revealed active cancer in the uterus and para-aortic lymph nodes. DISCUSSION: Since pembrolizumab treatment had to be discontinued, we performed salvage surgery, which achieved complete tumour removal, and the patient has had no evidence of disease for 16 months. CONCLUSION: This is the first case of complete surgical resection after administering pembrolizumab as a second-line treatment for advanced endometrial cancer. Elsevier 2022-04-27 /pmc/articles/PMC9118171/ /pubmed/35658296 http://dx.doi.org/10.1016/j.ijscr.2022.107125 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Taguchi, Tomomi Ito, Kimihiko Yamashita, Michiko Egawa-Takata, Tomomi Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report |
title | Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report |
title_full | Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report |
title_fullStr | Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report |
title_full_unstemmed | Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report |
title_short | Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report |
title_sort | complete resection after pembrolizumab treatment followed by salvage surgery in stage ivb endometrial cancer: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118171/ https://www.ncbi.nlm.nih.gov/pubmed/35658296 http://dx.doi.org/10.1016/j.ijscr.2022.107125 |
work_keys_str_mv | AT taguchitomomi completeresectionafterpembrolizumabtreatmentfollowedbysalvagesurgeryinstageivbendometrialcanceracasereport AT itokimihiko completeresectionafterpembrolizumabtreatmentfollowedbysalvagesurgeryinstageivbendometrialcanceracasereport AT yamashitamichiko completeresectionafterpembrolizumabtreatmentfollowedbysalvagesurgeryinstageivbendometrialcanceracasereport AT egawatakatatomomi completeresectionafterpembrolizumabtreatmentfollowedbysalvagesurgeryinstageivbendometrialcanceracasereport |